Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience

Siddhartha Ganguly, Jaswinder Singh, Clint L. Divine, Delva Deauna-Limayo, David C. Bodensteiner, Jan L. Lewis, Kathy Curran, Barry S. Skikne

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

In an attempt to examine whether autologous SCT provides long-term disease control in patients with intermediate and high-risk AML where a suitable donor is not available, we analyzed the outcomes of autologous SCT in patients with intermediate and high-risk AML from 1986 to 2005. No relapses occurred after 2.2 years. The overall survival curve appears to have developed a plateau after 2.2 years. In conclusion, autologous SCT in patients with AML in whom an allogeneic transplantation is not feasible appears to be a safe alternative and a plateau in the survival curve indicates cure in a small proportion of patients.

Original languageEnglish (US)
Pages (from-to)1253-1257
Number of pages5
JournalLeukemia Research
Volume31
Issue number9
DOIs
StatePublished - Sep 2007

Keywords

  • Acute myeloid leukemia
  • Bone marrow transplantation
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience'. Together they form a unique fingerprint.

Cite this